  
  
G/MA/QR/N/GBR/1/Add.2  
5 août 2022 
(22-5846) Page: 1/6 
Comité de l'accès aux marchés  Original:  anglais  
 
  
NOTIFICATION PRÉSENTÉE CONFORMÉMENT À LA DÉCISION  
SUR LES PROCÉDURES DE NOTIFICATION DES  
RESTRICTIONS QUANTITATIVES  
(G/L/59/REV.1)  
ROYAUME -UNI 
Addendum  
La communication ci -après, datée du 3 août 2022, est distribuée à la demande de la délégation du 
Royaume -Uni. 
 
A. Membre notifiant: Royaume -Uni 
B. Date de la notification: 3 août 2022  
C. Première notification:  
 Oui 
 Non, dernière notification présentée dans le document: G/L/59/Rev.1  
D. Type de notification:  
 1. Complète (c'est -à-dire notification de toutes les restrictions quantitatives en vigueur)  
 2. Modifications apportées à une notification faite précédemment (G/MA/QR/N/GBR/1) qui 
sont de la nature  suivante:  
  2.1 introduction de nouvelles restrictions, telles qu'énumérées dans la section 1.  
  2.2 Suppression de restrictions, tel qu' indiqué plus bas dans la section G.  
  2.3 Modification d'une restriction notifiée précédemment, tel qu'indiqué dans la 
 section  1. 
 3. Notification inverse de restrictions maintenues par (Membre):  
E. La notification contient de s renseignements pour la période biennale (par 
exemple  2012 -2014): 2020-2022 et concerne des restrictions en vigueur depuis  le 
24 juin 2022  
F. La présente notification contient les renseignements1 ci-après:  
 Section 1:  Liste des restrictions quantitatives actuellement en vigueur.  
 Section 2:  Renvoi à d'autres notifications adressées à l'O MC et contenant des 
renseignements sur des restrictions quantitatives actuellement en vigueur, et 
renseignements additionnels.  
 
1 En anglais seulement.  G/MA/QR/N/GBR/1/Add.2  
- 2 - 
  G. Observations générales, y compris description de la suppression de restrictions 
notifiées au titre du point D.2.2 et date à laquelle elles ont cessé d'être 
appliquées.  
1. Le présent addendum modifie et remplace la restriction quantitative n°  21, notifiée 
dans le document  G/MA/QR/N/GBR/1. Cette notification met à jour la liste des codes de 
produits applicables aux médicaments vi sés et fournit de plus amples renseignements 
sur la désignation des produits.  
2. Le Royaume -Uni notifie le retrait net de 30 médicaments de la liste des médicaments 
nécessaires au traitement des patients du Royaume -Uni, à un moment où la COVID -19 
continue d'avoir une incidence sur la demande et sur l'offre  des médicaments dont 
l'export ation est restreinte dans certaines circonstances limitées lorsqu'ils sont déjà 
présents dans la chaîne d'approvisionnement du pays et sont destinés à ses patients.  
3. Ce sont des mesures temporaires, instaurées pour prévenir une grave pénurie de 
médicame nts nécessaires à la protection de la santé des personnes. Ces mesures sont 
réexaminées régulièrement et ne sont appliquées que lorsqu'il  ne peut être satisfait aux 
besoins essentiels par d'autres mesures. Le 15 décembre 2021, 47  médicaments ont 
été retiré s de la liste. Au 24  juin 2022, 32 autres médicaments avaient été retirés de la 
liste. Deux médicaments ont été ajoutés à la liste.  
4. La notification G/MA/QR/N/GBR/1 du Royaume -Uni comprenait des détails concernant 
l'Irlande du  Nord. La présente notifica tion ne modifie pas ces dispositions, qui 
continuent de s'appliquer.  
 
   
  G/MA/QR/N/GBR/1/Add.2  
- 3 - 
 
Section 1: List of quantitative restrictions that are currently in force  
 
QR
No. General 
description of the 
restriction  Type of 
restriction  
 Tariff line 
code(s) 
affected, 
based on  
HS (2022 ) Detailed Product 
Description  WTO Justification 
and Grounds for 
Restriction, e .g., 
Other International 
Commitments  National legal basis 
and entry into force   
 Administration, 
modification of 
previously notified 
measures, and 
other comments  
1 2 3 4 5 6 7 
1 Measures to 
regulate exports of 
certain 
medicaments.  CP-X Medicines fall 
under the 
following 
commodity 
codes:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3002.41.90  1. Heading 3002 - 
Classification  
Human blood; animal 
blood prepared for 
therapeutic, 
prophylactic or 
diagnostic uses; 
antisera, other blood 
fractions and 
immunological pro ducts, 
whether or not modified 
or obtained by means of 
biotechnological 
processes; vaccines, 
toxins, cultures of 
micro -organisms 
(excluding yeasts) and 
similar products; cell 
cultures, whether or not 
modified  
 
 
 
Product Description per 
Commodity Code under 
Heading 3002  
 
Vaccines, toxins, 
cultures of micro -
organisms (excluding 
yeasts) and similar 
products, Other  Article XX(b) GATT  
Protection of human, 
animal or plant life or 
health.  
 Regulation 43(2) of 
the Human M edicines 
Regulations 2012 
requiring wholesale 
dealers to ensure 
continued supply of 
medicinal products so 
that the needs of 
patients in the UK are 
met. Further details 
can be found through: 
https://www.legislatio
n.gov.uk/uksi/2012/1
916/contents/made  
 
The date restrictions 
came into effect varies 
by medicine; this is 
specified for each 
medicine on the list, 
updated on 
24 June 2022 and 
available on gov.uk at  
 
https://assets.publishi
ng.service.gov.uk/gov
ernment/uploads/syst
em/uploads/attachme
nt_data/file/1042790/
restricted -medicines -
list-december -2021-
v3.csv/preview   
 
 The list of medicines 
is maintained by the 
Department of Health 
and Social Care.  
 
These measures are 
reviewed regularly.  
A full change log of 
previous measures, 
from October 2019, 
can be found here:  
https://www.gov.uk/
government/publicati
ons/medicines -that-
cannot -be-parallel -
exported -from-the-
uk  
 
Medicines included 
on this list meet the 
following conditions:  
• The medicine is 
required to meet 
the needs of UK 
patients  
• The medicine is 
currently in 
shortage or risk 
of being in 
shortage  
• The export of 
the medicine 
would contribute 
to or exacerbate 
a sho rtage, or 
risk of shortage,   
  G/MA/QR/N/GBR/1/Add.2  
- 4 - 
 
QR
No. General 
description of the 
restriction  Type of 
restriction  
 Tariff line 
code(s) 
affected, 
based on  
HS (2022 ) Detailed Product 
Description  WTO Justification 
and Grounds for 
Restriction, e .g., 
Other International 
Commitments  National legal basis 
and entry into force   
 Administration, 
modification of 
previously notified 
measures, and 
other comments  
1 2 3 4 5 6 7 
of that medicine 
in the UK  
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3004.20.00  
 
 
 
 
 
 
3004.31.00  
 
 
 
3004.32.00  
 
 
 
 
 
3004.39.00  
 
 
 
3004.49.00  2. Heading 3004 - 
Classification  
Medicaments consisting 
of mixed or unmixed 
products for therapeutic 
or prophylactic uses, put 
up in measured doses 
(including those in the 
form of transdermal 
administration systems) 
or in forms or packings 
for retail sale  
 
Product Description per 
Commodity Code under 
Heading 3004  
Other, containing 
antibiotics  
 
Other, containing 
hormones or other 
products of heading 
2937 
Containing insulin  
 
 
 
Containing 
corticosteroid 
hormones, their 
derivatives or structural 
analogues  
 
Other  
 
  
  Medicines on this list 
which  have been 
produced to fulfil 
contracts overseas 
are not subject to 
restriction. As such, 
restrictions only 
apply to wholesaler 
dealer license 
holders that are not 
the market 
authorisation holder 
for a medicine 
intended for export. 
The measures are 
designe d to ensure 
wholesalers fulfil 
their legal 
obligations to 
maintain supply to 
UK patients.  
 
These restrictions 
are only applied and 
maintained where  
alternative measures 
are not considered 
sufficient on their 
own to ensure that 
UK supply meets 
demand.  
A number of 
exemptions apply to 
medicines in scope 
of these restrictions. 
For example, exports 
destined for 
international   
  G/MA/QR/N/GBR/1/Add.2  
- 5 - 
 
QR
No. General 
description of the 
restriction  Type of 
restriction  
 Tariff line 
code(s) 
affected, 
based on  
HS (2022 ) Detailed Product 
Description  WTO Justification 
and Grounds for 
Restriction, e .g., 
Other International 
Commitments  National legal basis 
and entry into force   
 Administration, 
modification of 
previously notified 
measures, and 
other comments  
1 2 3 4 5 6 7 
 
 
 
 
3004.90.00  Other, containing 
alkaloids or derivatives 
thereof, Other  
 
 
Other  
Further detail of these 
medicines can be found 
at  
https://www.gov.uk/gov
ernment/publications/m
edicines -that-cannot -be-
parallel -exported -from-
the-uk 
 
These restrictions apply 
in certain circumstances 
to exports of specified 
medicines which are 
placed on the UK 
market for UK patients 
and needed to protect 
human health, including 
to treat Covid -19, 
inter alia. 
 
 humanitarian 
organisations such 
as COVAX are not 
covered. A full list of 
exemptions can be 
found at 
https://www.gov.uk/
government/publicati
ons/medicines -that-
cannot -be-parallel -
exported -from-the-
uk 
 
Requests for 
exemptions are 
considered on a 
case-by-case basis. 
These can be 
submitted by a 
foreign government  
or government 
agency, or a 
wholesaler on their 
behalf at 
restrictedmedicines
@dhsc.gov.uk  
 
Further information 
on these measures is 
available here:  
https://www.gov.uk/
guidance/parallel -
export -and-
hoarding -of-
restricted -medicines    
  G/MA/QR/N/GBR/1/Add.2  
- 6 - 
 
QR
No. General 
description of the 
restriction  Type of 
restriction  
 Tariff line 
code(s) 
affected, 
based on  
HS (2022 ) Detailed Product 
Description  WTO Justification 
and Grounds for 
Restriction, e .g., 
Other International 
Commitments  National legal basis 
and entry into force   
 Administration, 
modification of 
previously notified 
measures, and 
other comments  
1 2 3 4 5 6 7 
       It is the 
responsibility of the 
wholesaler to ensure 
any exports are 
made or withheld in 
compliance with 
these restrictions. 
Failure to comply 
with these 
restrictions may lead 
to regulatory action 
by the Medicines and 
Healthcare products 
Regulatory Authority 
(MHRA) against the 
wholesale dealer's 
licence.  
There are no 
additional steps or 
declarations required 
from a customs 
perspective.  
 
__________  